Inspire Medical Systems (INSP) AI Stock Analysis

• Market Cap: $2.13B
• Dividend Yield: N/A
• Average Volume (3M): 986.05K
• Price to Earnings (P/E): 41.8
• Beta (1Y): 0.41
• Revenue Growth: 22.05%
• EPS Growth: 785.52%
• Country: US
• Employees: 1,246
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.45
• Shares Outstanding: 29,574,316
• 10 Day Avg. Volume: 948,834
• 30 Day Avg. Volume: 986,046
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.67
• Enterprise Value/Revenue: 4.13
• Enterprise Value/Gross Profit: 4.89
• Enterprise Value/Ebitda: 43.85
• 1Y Price Target: $122.31
• Price Target Upside: 69.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 16

• Rating: 63 Neutral
• Price Target: $77.00 ▲(6.83% Upside)

Inspire Medical Systems' overall stock score is primarily influenced by its strong financial performance, despite challenges in profitability and cash flow conversion. Technical analysis indicates bearish momentum, while valuation metrics suggest the stock is overvalued. The mixed sentiment from the earnings call, with significant lowlights, further impacts the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and successful product adoption, supporting long-term business expansion.

Gross Profit Margin

A high gross profit margin reflects efficient cost management and pricing power, contributing to sustainable profitability.

Medicare Reimbursement Proposal

Increased Medicare reimbursement enhances affordability for patients, potentially expanding the customer base and driving revenue growth.

Negative Factors

Guidance Revision

Reduced revenue guidance suggests potential challenges in market penetration or operational execution, impacting growth expectations.

Challenges with Inspire V Rollout

Rollout challenges for new products can hinder adoption rates and delay revenue realization, affecting competitive positioning.

Increased Operating Expenses

Rising operating expenses can pressure margins and reduce profitability, limiting financial flexibility for future investments.

Inspire Medical Systems Business Overview & Revenue Model

Company Description

Inspire Medical Systems, Inc. is a medical technology company focused on developing innovative solutions for patients suffering from obstructive sleep apnea (OSA). The company is primarily engaged in the design and commercialization of its flagship product, the Inspire therapy system, which is a surgically implanted device that stimulates the hypoglossal nerve to maintain an open airway during sleep. Inspire operates within the healthcare sector, targeting both patients and healthcare providers, aiming to enhance treatment options for sleep apnea beyond traditional CPAP devices.

How the Company Makes Money

Inspire Medical Systems generates revenue primarily through the sale of its Inspire therapy system, which includes the implantation device and related components. The company also earns income from the ongoing sale of accessories and follow-up care associated with the therapy. Revenue is driven by hospital and surgical center partnerships where the Inspire system is implemented, and the company often collaborates with healthcare professionals to promote and educate about the benefits of its therapy. Additionally, reimbursement from insurance providers plays a crucial role in the company's earnings, as it allows patients to afford the therapy, thereby expanding the potential customer base.

Inspire Medical Systems Financial Statement Overview

Summary

Inspire Medical Systems demonstrates strong revenue growth and efficient cost management, reflected in its high gross profit margins. The company maintains a robust balance sheet with low leverage, enhancing its financial stability. While cash flow metrics show positive trends, there is room for improvement in converting net income into free cash flow.

Income Statement

Inspire Medical Systems has shown consistent revenue growth with a TTM revenue growth rate of 2.52%. The company maintains a strong gross profit margin of 84.47% in TTM, indicating efficient cost management. However, the net profit margin is relatively low at 6.17%, suggesting room for improvement in profitability. The EBIT and EBITDA margins have improved over the years, reflecting better operational efficiency.

Balance Sheet

The company has a solid balance sheet with a low debt-to-equity ratio of 0.048, indicating low leverage and financial stability. The return on equity is positive at 7.87% in TTM, showing effective use of equity to generate profits. The equity ratio is strong, reflecting a healthy capital structure with a significant portion of assets financed by equity.

Cash Flow

Inspire Medical Systems exhibits a positive trend in free cash flow growth, with a 7.81% increase in TTM. The operating cash flow to net income ratio is 1.26, indicating good cash generation relative to net income. However, the free cash flow to net income ratio of 0.72 suggests that not all net income is translating into free cash flow, which could be a point of concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	861.31M	802.80M	624.80M	407.86M	233.39M	115.38M
Gross Profit	727.54M	679.82M	528.22M	341.74M	200.12M	97.76M
EBITDA	81.21M	65.03M	-17.06M	-39.69M	-38.62M	-53.16M
Net Income	53.12M	53.51M	-21.15M	-44.88M	-42.04M	-57.20M
Balance Sheet
Total Assets	802.19M	808.38M	676.81M	564.88M	295.08M	281.19M
Cash, Cash Equivalents and Short-Term Investments	300.89M	445.55M	460.38M	451.41M	214.47M	234.36M
Total Debt	33.06M	31.79M	24.85M	8.87M	34.09M	30.63M
Total Liabilities	124.38M	118.69M	104.30M	68.87M	66.04M	51.44M
Stockholders Equity	677.81M	689.70M	572.51M	496.01M	229.05M	229.75M
Cash Flow
Free Cash Flow	85.01M	91.12M	1.02M	2.47M	-24.79M	-55.50M
Operating Cash Flow	117.44M	130.25M	24.65M	11.57M	-20.12M	-53.05M
Investing Cash Flow	-54.20M	-113.12M	-294.82M	-19.60M	29.14M	86.63M
Financing Cash Flow	-144.31M	-52.39M	13.95M	235.08M	14.95M	134.06M

Inspire Medical Systems Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 72.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INSP, the sentiment is Negative. The current price of 72.08 is below the 20-day moving average (MA) of 77.82, below the 50-day MA of 80.79, and below the 200-day MA of 131.79, indicating a bearish trend. The MACD of -1.67 indicates Positive momentum. The RSI at 35.45 is Neutral, neither overbought nor oversold. The STOCH value of 5.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INSP.

Inspire Medical Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TMDX	―	$4.50B	53.13	32.48%	―	41.20%	173.53%
INSP	―	$2.13B	41.76	8.07%	―	22.05%	785.52%
ITGR	―	$2.26B	27.03	5.18%	―	7.81%	-26.32%
IRTC	―	$6.03B	―	-53.15%	―	25.45%	66.62%
LIVN	―	$2.87B	―	-17.87%	―	8.57%	-1154.64%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRCT	―	$1.89B	―	-26.40%	―	55.71%	24.37%

Inspire Medical Systems Corporate Events

Inspire Medical’s EURO-STIM Registry: A Long-Term Look at Sleep Apnea Treatment

Study Overview: The EURO-STIM Registry, officially titled ‘Longitudinal Outcomes and Adherence of the Inspire System, EURO-STIM Registry,’ aims to measure the long-term outcomes and adherence of the Inspire System in patients with Obstructive Sleep Apnea (OSA). This study is significant as it seeks to capture the life cycle of the patient’s use of the Inspire System through routine clinical care visits, providing valuable insights into its effectiveness and patient adherence over time.

Inspire Medical’s New Study: Expanding Horizons for OSA Treatment

Inspire Medical Systems, Inc. is conducting a significant clinical study titled ‘Inspire UAS High AHI/High BMI Post-Approval Study.’ The study aims to evaluate the long-term safety and effectiveness of the Inspire® UAS System in patients with obstructive sleep apnea (OSA) who have a higher Apnea Hypopnea Index (AHI) and Body Mass Index (BMI). This research is crucial as it expands the patient population for this treatment, potentially offering new hope for those with severe OSA conditions.

Inspire Medical’s Pediatric Study: A Closer Look at the OSA Treatment Registry

Study Overview: The Inspire Pediatric Post-Approval Registry aims to evaluate the long-term safety and effectiveness of the Inspire Upper Airway Stimulation (UAS) System in pediatric patients aged 18-21 years with moderate to severe obstructive sleep apnea (OSA). This multi-center, single-arm study is significant as it seeks to provide critical data on the system’s performance over a five-year period post-implant.

Inspire Medical’s New Study on Sleep Apnea in Down Syndrome Patients: A Market Game Changer?

Inspire Medical Systems, Inc. has launched the Pediatric Down Syndrome Post-Approval Study to evaluate the safety and effectiveness of the Inspire therapy in adolescents and young adults with Down syndrome and severe sleep apnea. This study aims to provide ongoing assessments of the Inspire UAS System in this specific population, highlighting its significance in improving patient outcomes.

Inspire Medical Systems Unveils Positive Data for Inspire V

In October 2025, Inspire Medical Systems published clinical outcomes data for their Inspire V system at the ISSS/AAO-HNS meetings in Indianapolis. The data, from a Singapore study and a limited U.S. market release, showed significant improvements in patient adherence, safety, and surgical efficiency compared to previous models. The Inspire V system demonstrated a 20% reduction in surgical times and superior respiratory sensing, leading to enhanced patient comfort and therapy outcomes. The results indicate a promising advancement in treating obstructive sleep apnea, with implications for increased adoption and potential changes in reimbursement levels.

The most recent analyst rating on (INSP) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.

Inspire Medical Systems CFO to Step Down

Inspire Medical Systems announced that its Chief Financial Officer, Richard J. Buchholz, will step down from his position effective December 31, 2025, to pursue other professional opportunities. Buchholz will remain in a financial advisory role until February 28, 2026, to ensure a smooth transition. The company has initiated a search for a new CFO and reaffirmed its 2025 financial guidance with expected revenues between $900 to $910 million. Buchholz has been instrumental in the company’s growth, contributing to its revenue increase from $4 million to over $800 million in 2024 and guiding it through its IPO and the challenges of the COVID-19 pandemic.

The most recent analyst rating on (INSP) stock is a Hold with a $97.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.

Inspire Medical Systems Announces $200M Share Buyback

On August 11, 2025, Inspire Medical Systems announced that its Board of Directors authorized a share repurchase program of up to $200 million. This decision reflects the company’s confidence in its growth prospects and the belief that its stock is undervalued. The repurchase program is part of a broader strategy to support the launch of Inspire V, their next-generation neurostimulation system, and to return capital to shareholders while continuing to invest in future growth.

The most recent analyst rating on (INSP) stock is a Hold with a $200.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.

Inspire Medical’s Mixed Earnings Call: Growth Amid Challenges

The recent earnings call for Inspire Medical Systems presented a mixed sentiment, highlighting significant revenue growth and promising advancements in the Inspire V system. However, these positive developments were somewhat overshadowed by challenges in executing the transition to the new system and a reduction in financial guidance.

Inspire Medical Systems Reports Q2 2025 Financials

Inspire Medical Systems, Inc. is a medical technology company that specializes in developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea. The company’s proprietary Inspire therapy is the first FDA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea.

Inspire Medical Systems Reports Q2 2025 Financial Results

Inspire Medical Systems announced its financial results for the second quarter of 2025, reporting a revenue of $217.1 million, an 11% increase from the previous year. Despite achieving a gross margin of 84%, the company faced an operating loss of $3.3 million, partly due to a $4.0 million non-cash impairment of a strategic investment. The company also launched its Inspire V neurostimulation system in the U.S., which has received positive feedback but is experiencing slower-than-expected commercial progress, impacting financial results for the year. Executive Vice President Randall A. Ban announced his retirement effective January 30, 2026, marking the end of his influential tenure at the company.

The most recent analyst rating on (INSP) stock is a Hold with a $200.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.